Psychedelic drugs like psilocybin and LSD have been investigated for their anti-anxiety (anxiolytic) potential in people with end-of-life anxiety associated with severe illness, but the anxiolytic effects of LSD-assisted therapy had not yet been assessed in patients with anxiety disorders without life-threatening illness.
Researchers suggest that the benefits of psychedelic treatment are mediated by a reduction in death anxiety and existential distress.
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.
Researchers see value in a naturalistic approach to psychedelic studies.
Terminal patients are learning to live, not just preparing to die.
Psilocybin may help suicidal patients renew their sense of meaning.
Psychedelics may be a valuable aid when it’s time to take the ultimate journey.
“…this stands up to scientific rigor and is worthy of further exploration.”
The MEQ is a self-report measure that provides insight into a key aspect of the psychedelic experience.